Celgene Shares Good News On Ozanimod, Quietly Dumps Pricey GED-0301
Executive Summary
Strong Q1 results and a plan to refile ozanimod in early 2019 may help investors regain confidence in Celgene, but a lot depends on the company's pipeline, which had an additional setback with discontinuation of all GED-0301 development.